By the time most retail biotech investors open a Form 4, the stock has already moved. The filing was public for days — sometimes weeks — but nobody without a Bloomberg terminal has the hours to go looking. That gap is the whole reason this newsletter exists.
Every week, I manually go through the 8-Ks, 10-Qs, and Form 4s of 150 small-cap biotech companies, all under $2B in market cap. I'm watching for three things: insider buys and sells above $50K, upcoming FDA and PDUFA catalyst dates, and unusual changes in filing language — a going-concern warning that wasn't there last quarter, new restructuring wording, risk factors that quietly shifted.
The free tier gets the catalyst calendar. Paid subscribers also get the insider-trading watch and the filing-language analysis, which is where the real work happens.
Here's what a typical issue looks like. It opens with the calendar: every FDA decision date and PDUFA date coming up across the 150 companies, so you know when the binary events land before they're in your face. Next, the insider transactions — who bought, who sold, and whether it was one executive or several people at once. I close with the filings where the language changed, quoted directly, with a short note on why it caught my eye. No price targets, no ratings. Just what was filed, when, and what it might mean.
An example of the kind of pattern worth paying for: an insider buy over $50K is interesting on its own. The same buy, filed two weeks before a PDUFA date, at a company whose last quarterly report turned noticeably more cautious — that's a different animal. A screener will show you the Form 4. It won't put the buy next to the calendar and the filing language, because those three things live in different places and nobody has time to cross-reference all 150 companies by hand. I do, every week.
That's also the honest limitation: this is not automated. It's a human reading filings and making judgment calls, which is slower than a bot but exactly why it notices things algorithms miss. If you trade small-cap biotech without a terminal, this is the portion of the tape you've been missing — and I'd rather you know precisely how it's built before you subscribe.